Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma

Drug Safety

Mats Carlsson,[1] Martin Braddock,[2] Yuling Li,[3] Jihong Wang,[3] Weichen Xu,[3] Nicholas White,[4] Ayman Megally,[5] Gillian Hunter,[6] Gene Colice[5]

[1]Patient Safety, Global Medicines Development, AstraZeneca, Pepparedsleden 1, Mölndal, SE-431 83, Sweden

[2]Global Medicines Development, AstraZeneca, Granta Park, Great Abington, Cambridge, CB21 6GH, United Kingdom

[3]Biopharmaceutical Development, MedImmune, One MedImmune Way, Gaithersburg, Maryland 20878, United States

[4]Clinical Pharmacology, Pharmacometrics and DMPK, MedImmune, Granta Park, Great Abington, Cambridge, CB21 6GH, United Kingdom

[5]Global Medicines Development, AstraZeneca, One MedImmune Way, Gaithersburg, Maryland 20878, United States

[6]Biometrics and Information Sciences, AstraZeneca, Granta Park, Great Abington, Cambridge, CB21 6GH, United Kingdom

Corresponding author: Mats Carlsson, Patient Safety, Global Medicines Development, AstraZeneca, Pepparedsleden 1, Mölndal, SE-431 83, Sweden.

Mats.Carlsson@astrazeneca.com

Electronic Supplementary Material 2

Fc glycosylation variants in tralokinumab across different manufacturing lots

Lot number	Afucosyl-ation (%)	Galactosyl-ation (%)	α-Gal (%)	Sialylation (%)	High-mannose (%)	Aglycosyl-ation (%)
1	2.2	30.4	3.7	13.7	1.7	1.0
2	1.9	36.1	4.2	17.3	1.5	1.3
3	1.7	43.8	5.7	21.3	1.3	2.0
4	1.7	50.2	9.0	22.8	1.3	2.1
5	1.7	44.2	6.3	20.8	1.4	1.7
6	1.5	42.5	5.7	24.1	1.1	1.4
7	1.6	41.8	3.8	12.4	1.2	1.2
8	1.7	33.6	1.4	5.5	1.1	1.0
9	0.7	32.3	2.4	5.4	0.7	1.3
10	1.1	38.2	3.3	3.9	0.7	1.8
11	0.9	45.7	5.1	12.6	0.7	0.9
12	0.7	46.7	7.7	14.1	0.5	0.7
13	0.5	50.6	8.5	15.3	0.4	0.5
14	0.4	50.8	9.4	15.2	0.4	0.4
15	0.5	45.4	4.2	10.9	0.5	0.5
16	0.6	46.1	4.5	11	0.6	0.6
17	1.0	37.1	2.3	11.4	0.8	1.0
18	1.2	37.4	3.2	10.8	0.8	1.2
19	1.2	40.1	3.1	11.6	0.9	1.2

α-Gal, galactose-α-1,3-galactose